Hepatic Encephalopathy
Clinical research focuses on overt hepatic encephalopathy and the prevention of encephalopathy-related deterioration in people with cirrhosis. The sponsored studies address treatment areas linked to HE-related hospitalization and delayed decompensation.
- Overt hepatic encephalopathy
- Encephalopathy decompensation in cirrhosis
- HE-related hospitalization
These investigations reflect a therapeutic interest in liver-related neurocognitive complications and their clinical consequences.
Hepatic Impairment
Research activity also includes hepatic impairment, with attention to how reduced liver function affects the handling of therapeutic agents in adults with impaired hepatic function.
- Impaired hepatic function
- Pharmacokinetics in liver dysfunction
- Adult subjects with hepatic impairment
This area supports clinical interest in liver disease populations where altered metabolism and clearance are medically relevant.
Gastroenterology and Liver Disease
The sponsor’s portfolio is centered on gastroenterology and hepatology, particularly conditions arising from chronic liver disease and cirrhosis. The funded studies align with management of complications associated with advanced liver dysfunction.
- Hepatology
- Cirrhosis-associated complications
- Chronic liver disease
Clinical interest is directed toward liver-related disorders that affect neurological status and overall disease burden.
Rifaximin-Based Therapeutic Development
Trial activity includes work involving rifaximin formulations, with emphasis on a soluble solid dispersion approach in liver-compromised populations. The research landscape is tied to treatment development for encephalopathy and hepatic dysfunction.
- Rifaximin formulations
- Soluble solid dispersion
- Liver-compromised patient populations
This focus connects anti-infective gastrointestinal therapy with liver disease management.
